



CASE 4-20251C/C1C1/MA 2102

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV041586727US
Express Mail Label Number

February 12, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1642

TAYLOR ET AL.

APPLICATION NO: 10/001,755

FILED: OCTOBER 24, 2001

FOR: LIPOSOMAL INTERFERON HYBRID COMPOSITION

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. The listed references are of record in parent Application No. 09/257,446 filed February 25, 1999, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6950

Date: February 12, 2002


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940